Research Project

Project Title:	A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PARALLEL-GROUP, ACTIVE-CONTROL STUDY OF THE EFFICACY AND SAFETY OF SPARSENTAN FOR THE TREATMENT OF IMMUNOGLOBULIN A NEPHROPATHY- 021IGAN17001
Project Type:	Clinical Trial, Enrolment terminated
Disease group(s):	Immune glomerulopathies
Project Summary:	To determine the effect of sparsentan on proteinuria and preservation of renal function, as compared to an angiotensin receptor blocker (ARB), in patients with immunoglobulin A nephropathy (IgAN). To assess the safety and tolerability of sparsentan by double-blind monitoring of safety endpoints.
Lead principal investigator(s):	Loreto Gesualdo, Bari
Co-investigator(s):	F Annese , Bari F Papadia, Bari Vincenzo Di Leo, Bari
Project Period:	01/2020 - 07/2026
Sponsors:	Industry
EudraCT Nr.:	2017-004605-41